Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS [Yahoo! Finance]
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: Yahoo! Finance
HTA assessments highlight importance of timely and equitable access to QALSODY for this ultra-rare genetic form of ALS and urgent need for therapies that slow progression, preserve function and independence, extend survival, and improve quality of life TORONTO Dec. 11, 2025 /CNW/ - Biogen Canada Inc. is encouraged by the recent Health Technology Assessment (HTA) evaluations issued by Canada's Drug Agency (CDA) and the Institut national d'excellence en santé et en services sociaux (INESSS) for QALSODY™ (tofersen injection), the first therapy designed to target a known genetic cause of amyotrophic lateral sclerosis (ALS). CDA Issues Positive Reimbursement Recommendation CDA, through the Canadian Drug Expert Committee (CDEC), issued a positive reimbursement recommendation for QALSODY for adults with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. The recommendation highlights CDEC evaluations that data from the Phase 3 VALOR
Show less
Read more
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- Biogen (NASDAQ:BIIB) was given a new $156.00 price target on by analysts at Morgan Stanley.MarketBeat
- Biogen (NASDAQ:BIIB) was downgraded by analysts at Hsbc Global Res from a "hold" rating to a "moderate sell" rating.MarketBeat
- Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wells Fargo & Company from $155.00 to $190.00. They now have an "equal weight" rating on the stock.MarketBeat
- Biogen (NASDAQ:BIIB) was downgraded by analysts at HSBC Holdings plc from a "hold" rating to a "reduce" rating.MarketBeat
- Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual MeetingGlobeNewswire
BIIB
Earnings
- 10/31/25 - Beat
BIIB
Sec Filings
- 12/3/25 - Form 4
- 11/13/25 - Form SCHEDULE
- 11/10/25 - Form SCHEDULE
- BIIB's page on the SEC website